CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A

138
Loading...
Loading...
News
all
press releases
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·9mo ago
News Placeholder
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·9mo ago
News Placeholder
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·10mo ago
News Placeholder
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·10mo ago
News Placeholder
Contineum Therapeutics to Attend Upcoming Investor Conferences
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·10mo ago
News Placeholder
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways...
Business Wire·11mo ago
News Placeholder
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways...
Business Wire·1y ago
News Placeholder
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways...
Business Wire·1y ago
News Placeholder
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways...
Business Wire·1y ago

Latest CTNM News

View

Advertisement. Remove ads.

Advertisement. Remove ads.